$XAIR News

Last published 21h ago

21h agoXAIRBeyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026GlobeNewswireRecord quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH
2w agoXAIRBeyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026GlobeNewswireGARDEN CITY, N.Y., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on
2mo agoXAIRBeyond Air to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewswireGARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
2mo agoXAIRBeyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)GlobeNewswireGARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on
2mo agoXAIRBeyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone PaymentsGlobeNewswireBeyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments
3mo agoXAIRBeyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate UpdateGlobeNewswireReports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review;
3mo agoXAIRBeyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026GlobeNewswireGARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on
3mo agoXAIRBeyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireGARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on
4mo agoXAIRBeyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate UpdateGlobeNewswireRevenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31st to
4mo agoXAIRBeyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and WebcastGlobeNewswireGARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on
5mo agoXAIRBeyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special MeetingGlobeNewswireSpecial Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included
5mo agoXAIRBeyond Air Receives Nasdaq Hearing Panel Decision Granting Continued ListingGlobeNewswireGARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
6mo agoXAIRBeyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026GlobeNewswireUpdated AACR poster data show continued survival follow-up in heavily pre‑treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas delivery technology for UNO
7mo agoXAIRBeyond Air to Participate in the D. Boral Capital Global Conference 2026GlobeNewswireGARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
7mo agoXAIRBeyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)GlobeNewswireGARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
7mo agoXAIRBeyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEOGlobeNewswireGARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
8mo agoXAIRBeyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.GlobeNewswireGARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
8mo agoXAIRBeyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory InfectionsGlobeNewswireGARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
9mo agoXAIRBeyond Air, Inc. Third Quarter 2026 Earnings Call - BEYOND AIR INCEarnings Call TranscriptsGood morning, and welcome, everyone, to Beyond Air Financial Results Call for the Fiscal Quarter ended December 31, 2025. At this time, all participants are in listen-only mode. A question-and-answer session will follow
9mo agoXAIRBeyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireIncreased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable
9mo agoXAIRBeyond Air - Noble Capital Markets Virtual Equity Conference - BEYOND AIR INCEarnings Call TranscriptsI'm Robert LaBoyer, Senior Biotechnology Analyst at Noble Capital Markets. Our next presenting company is Beyond Air, a company developing nitric oxide therapies for therapeutic uses. With us to present is CEO and Chairm
9mo agoXAIRBeyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026GlobeNewswireGARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and
9mo agoXAIRBeyond Air to Participate in Two Upcoming Healthcare Investor ConferencesGlobeNewswireGARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
9mo agoXAIRBeyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and WebcastGlobeNewswireGARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
9mo agoXAIRBEYOND AIR FIRESIDE CHAT @ LYTHAM PARTNERS 2026 INVESTOR HEALTHCARE SUMMIT - BEYOND AIR INCEarnings Call TranscriptsHello, and welcome to the Beyond Air Fireside Chat. My name is Roger Weiss, and I'm a Vice President here at Lithium Partners. Today, I'll be moderating a Q&A discussion with Steve Lissy, CEO and Chairman of the board at
10mo agoXAIRBeyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireGARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
10mo agoXAIR XTLBXTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific LeadershipGlobeNewswireUnmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying
10mo agoXAIR XTLBXTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific LeadershipGlobeNewswireUnmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying
10mo agoXAIRBeyond Air® Appoints Dan Moorhead as Chief Financial OfficerGlobeNewswireGARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
11mo agoXAIRBeyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and BrazilGlobeNewswireGARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
11mo agoXAIRBeyond Air® Announces Transition of Chief Financial OfficerGlobeNewswireGARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBeyond Air, Inc. Second Quarter 2026 Earnings Call - BEYOND AIR INCEarnings Call TranscriptsGood afternoon, and welcome to the Beyond Air Financial Results Call for the Fiscal Quarter ended September 30, 2025. At this time, participants are in a listen-only mode. A question-and-answer session will follow the fo
1y agoXAIRBeyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireIncreased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents,
1y agoXAIRBeyond Air® Secures Up to $32 Million to Accelerate GrowthGlobeNewswireEnters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of
1y agoXAIRBeyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and WebcastGlobeNewswireGARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBeyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities ConferenceGlobeNewswireGARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBeyond Air Announces Exercise of Warrants for $3.25 Million of Gross ProceedsGlobeNewswireGARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRNeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in AdultsGlobeNewswireBOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ:XAIR), today
1y agoXAIRBeyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireGARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBeyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in JapanGlobeNewswireGARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBeyond Air, Inc. (XAIR) Q1 2026 Earnings Call TranscriptEarnings Call Transcripts
1y agoXAIRBeyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireIncreased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more
1y agoXAIRBeyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and WebcastGlobeNewswireGARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBeyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.GlobeNewswireGARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBEYOND AIR LTD - Appeal, Affirmed-in-PartUS Patent Trial and Appeal Board
1y agoXAIRBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireRevenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue
1y agoXAIRBeyond Air Submits FDA PMA Supplement for Next Generation LungFit® PHGlobeNewswireLungFit PH II's smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY,
1y agoXAIRBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastGlobeNewswireGARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)GlobeNewswireGARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of
1y agoXAIRNeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismGlobeNewswireThe FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating